The major companies in the market are Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc.

New York, March 04, 2022 (GLOBE NEWSWIRE) — announces the publication of the “Cardiovascular Drugs Global Market Report 2022” –
and Becton Dickinson.

The global cardiovascular drug market is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities that resulted in operational challenges. The market is expected to reach $173.48 billion in 2026 with a CAGR of 3.1%.

The cardiovascular drugs market includes the sales of cardiovascular drugs by entities (organizations, sole proprietorships, and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce antihypertensive drugs to prevent heart failure by controlling blood pressure and lipid-lowering drugs. which reduce the levels of lipids and lipoproteins in the blood.

It also includes establishments that produce antithrombotic drugs to treat arterial and venous thrombosis.

The main types of cardiovascular drugs are antihypertensives, hypolipidemics, antithrombotics and other drugs for cardiovascular diseases (congestive heart failure, antiarrhythmics and antianginals). Lipid-lowering drugs are a diverse class of drugs used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia).

Medicines are available as pharmaceutical drugs and biologics. Drugs are administered orally, parenterally and others which are classified into branded and generic drugs.

Medicines are distributed by hospital pharmacies, retail pharmacies/pharmacies and others.

North America was the largest region in the cardiovascular drug market in 2021. Middle East is expected to be the fastest growing region during the forecast period.

Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Rising sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world’s population, particularly non-communicable diseases such as cancer, diabetes and cardiovascular disease. Long working hours, less physical activity, and poor eating and drinking habits are major causes of cardiovascular disease, including hypertension.

According to the World Health Organization, the prevalence of chronic diseases increased by 57% globally in 2020. These factors are expected to increase the number of patients globally, thereby driving the cardiovascular drug market over the period of forecast.

The high costs associated with medications are a major problem faced by citizens of many countries. The pressure to contain costs and demonstrate value is pervasive.

Political uncertainty and continuing economic tensions in many countries call into question the sustainability of public financing of health care. In less affluent countries, the lack of cost-effective medicines has influenced the health conditions of the population and led to a low average life expectancy.

As a result, in countries like Chad, Macedonia, Serbia, pharmaceutical companies are facing pressure to reduce drug prices. High drug costs are putting pressure on the revenues of cardiovascular drug manufacturers.

NOACs are increasingly accepted and are replacing traditionally used anticoagulants such as warfarin and heparin. Anticoagulants have long been used in the prevention of thrombus formation in patients with cardiovascular disease.

The use of NOACs makes it easier for patients to continue treatment after discharge, unlike heparin and warfarin injections which require medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.

The countries covered in the Cardiovascular Drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway , Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United Kingdom, United States, Venezuela and Vietnam.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001